Reviewed by: Jose Baldazo, BSN, RN
Retatrutide showed up to 30% average weight loss in Phase 3 trials — but it's not FDA-approved yet. Here's what the data shows, how it compares to semaglutide and tirzepatide, and what its regulatory timeline actually looks like.
If you've spent any time near GLP-1 conversations lately, you've probably heard "retatrutide" mentioned as the next big thing after semaglutide and tirzepatide — sometimes with numbers that sound almost too large to believe. Some of those numbers are real. Others get repeated without the context that actually matters: retatrutide is not FDA-approved, and understanding where it stands right now takes more than a headline stat.
Here's what the actual trial data shows, how retatrutide differs mechanically from the GLP-1 medications already on the market, and what its realistic timeline looks like.
Want to learn more about GLP-1s? Book a free info call
What retatrutide actually is
Retatrutide is a triple-hormone-receptor agonist — it activates three separate receptors: GLP-1, GIP, and glucagon. That's a meaningful mechanical difference from semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP). The added glucagon-receptor activity is the piece researchers believe drives retatrutide's larger effect: glucagon receptor activation increases energy expenditure in addition to appetite suppression, which is a different mechanism than appetite reduction alone.
(Internal link opportunity: for patients comparing this to what your clinic currently offers, link "semaglutide" and "tirzepatide" to your relevant treatment pages.)
What the Phase 3 data actually shows
The headline numbers come from the TRIUMPH-1 trial, an 80-week, randomized, double-blind, placebo-controlled study of 2,339 adults with obesity or overweight and at least one weight-related condition (excluding participants with diabetes). Results by dose:
12 mg (highest dose): 28.3% average weight loss at 80 weeks, rising to 30.3% at 104 weeks
9 mg: 25.9% average weight loss
4 mg (lowest dose): 19.0% average weight loss
Notably, 45.3% of participants in the 12 mg group achieved 30% or greater body weight reduction — a result that approaches outcomes typically associated with bariatric surgery.
Separate Phase 3 trials (TRIUMPH-2 and TRIUMPH-3), reported in July 2026, extended these findings to patients with type 2 diabetes and cardiovascular disease, showing 21% and 23% average body weight reduction respectively over 80 weeks in those populations.
Side effects tracked with dose. Gastrointestinal effects were the most common adverse events at the 12 mg dose: nausea (42.4% vs. 14.8% placebo), diarrhea (32.0% vs. 13.5%), vomiting (25.3% vs. 4.8%), and constipation (26.1% vs. 10.9%). Discontinuation due to side effects also rose with dose — from 4.1% at the lowest dose to 11.3% at the highest.
Is retatrutide FDA-approved?
No — and this is the single most important thing to understand before anything else. As of now, retatrutide remains an investigational drug. Eli Lilly has stated it plans to submit its FDA application in the first quarter of 2027, having pushed back an original end-of-2026 target to allow additional time for manufacturing and quality-control data.
That means, realistically, retatrutide is not something a clinic can legally offer as an approved treatment today, and any timeline for approval, launch, or availability should be treated as an estimate, not a promise. Standard FDA review periods run several months to a year beyond a submission date, which means broad legal availability is unlikely before late 2027 or 2028 even if the Q1 2027 submission timeline holds.
How it compares to what's already available
Retatrutide's trial results are genuinely larger than the currently approved options — tirzepatide's own trials showed roughly 20% average weight loss at comparable doses and duration, and semaglutide's showed somewhat less. But "larger in a trial" and "right for a given patient" are different questions, and a few things are worth weighing:
More receptor targets can mean more side effects, not just more benefit — the GI side-effect rates above are not trivial, and they scaled with dose in the same trial that produced the headline weight-loss numbers.
Approved medications have years of real-world safety data that an investigational drug, by definition, does not yet have.
A larger number in a trial doesn't automatically mean a better fit for every patient — response varies individually, and the right medication depends on a person's full metabolic picture, not the newest compound's average trial result.
Book a consult to talk through which GLP-1 option fits you
What to do if you're interested in retatrutide
Since it isn't approved, the honest options today are limited, and it's worth naming them plainly:
Talk to a provider about what's approved and available now. Semaglutide and tirzepatide have substantial trial and real-world data behind them, and a personalized program built around one of them is a legitimate, available path today rather than a wait for something that may still be a year or more out.
The bottom line
Retatrutide's Phase 3 data is genuinely impressive — up to 30% average weight loss is a real number from a real trial, not marketing language. But "impressive trial data" and "available, approved treatment" are two different stages, and retatrutide is still in the first one. For now, the most productive conversation is about what's actually available and evidence-backed today, with retatrutide as something to watch rather than something to plan around.
Talk to a provider about our current weight loss program
Frequently Asked Questions
Is retatrutide FDA-approved? No. As of late 2026, retatrutide remains investigational. Eli Lilly plans to submit its FDA application in Q1 2027, with broad approval and availability unlikely before late 2027 or 2028.
How much weight can you lose on retatrutide? In the Phase 3 TRIUMPH-1 trial, participants on the highest (12 mg) dose lost an average of 28.3% of body weight at 80 weeks, rising to 30.3% at 104 weeks. Results varied by dose, with lower doses producing smaller average losses.
How is retatrutide different from tirzepatide or semaglutide? Retatrutide activates three hormone receptors (GLP-1, GIP, and glucagon), compared to two for tirzepatide (GLP-1, GIP) and one for semaglutide (GLP-1 only). The added glucagon activity is believed to drive additional weight loss through increased energy expenditure, not just appetite suppression.
Can I get retatrutide now? Not as an approved prescription. The only current legitimate access route is through an active clinical trial. Compounded or unregulated versions sold outside of trials are not FDA-approved or manufacturing-verified and carry meaningfully higher risk.
Sources & Further Reading
New England Journal of Medicine — Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. Peer-reviewed original trial data. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
American Journal of Managed Care (AJMC) — Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial. Phase 3 results summary. https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
BioPharma Dive — Lilly, with new data, to seek FDA approval of obesity drug retatrutide. Regulatory timeline and submission plans. https://www.biopharmadive.com/news/lilly-retatrutide-fda-application-obesity-drug-results/825987/
Eli Lilly and Company (Investor Relations) — Phase 2 retatrutide results as published in NEJM, press release. https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal
(Compliance note: retatrutide is not FDA-approved. This post is educational only and should not be read as promoting off-label or compounded access. Confirm current regulatory status and any claims about "our weight loss program" against what your clinic can legally offer before publishing — avoid language that could be read as offering or promoting retatrutide itself.)